enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Health Rounds: Next generation Lilly weight-loss drug shows ...

   www.aol.com/news/health-rounds-next-generation...

   At 48 weeks, for example, retatrutide had reduced levels of triglycerides by up to 40.6%, and levels of a protein called apoC-III involved in glucose metabolism and inflammation by 38%.

3. Retatrutide - Wikipedia

   en.wikipedia.org/wiki/Retatrutide

   Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist ( GLP-1 , GIP , and GCGR receptors). [ 1 ]

4. New weight loss drug retatrutide shows promise in trial ... - AOL

   www.aol.com/weight-loss-drug-retatrutide-shows...

   New weight loss drug retatrutide shows promise in trial, doctors say. Chloe Nordquist. July 13, 2023 at 2:08 PM. A closeup of a beam scale is seen in New York on April 3, 2018.

5. GLP1 poly-agonist peptides - Wikipedia

   en.wikipedia.org/wiki/GLP1_poly-agonist_peptides

   GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

6. Cagrilintide/semaglutide - Wikipedia

   en.wikipedia.org/wiki/Cagrilintide/semaglutide

   This pharmacology -related article is a stub. You can help Wikipedia by expanding it.

7. Experimental Weight-Loss Drug Retatrutide May Be More ... - AOL

   www.aol.com/experimental-weight-loss-drug...

   Eli Lily’s weight-loss drug retatrutide helped patients lose 24% of their body weight, new data shows. The results rivaled Ozempic. Experts share what to know.

8. Liraglutide - Wikipedia

   en.wikipedia.org/wiki/Liraglutide

   Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. [6] [7] It is a second-line therapy for diabetes following first-line therapy with metformin.

9. Is This Trend a Threat to Eli Lilly's Weight Loss Drug ... - AOL

   www.aol.com/trend-threat-eli-lillys-weight...

   The weight loss drug market is growing rapidly. Eli Lilly (NYSE: LLY) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but ...